SFJ Pharma announced a collaborative development agreement with Pfizer Inc. to conduct a Phase 3 clinical trial in Asia of Pfizer’s investigational agent axitinib for the adjuvant treatment of patients at high risk of recurrent renal cell carcinoma(RCC) following nephrectomy.

On January 9, 2012 SFJ Pharmaceuticals reported that it has entered into a collaborative agreement with Pfizer to conduct a Phase III clinical trial in Asia for Pfizer’s investigational agent axitinib for the adjuvant treatment of patients at high risk of recurrent renal cell carcinoma (RCC) following nephrectomy (Press release Pfizer, JAN 9, 2012, View Source [SID:1234500285]).
Under the terms of ageement, SFJ will provide the funding and clinical development supervision to generate the clinical data necessary to submit axitinib for review by regulatory authorities for the adjuvant treatment of patients at high ris of recurrent RCC following nephrectomy. SFJ will be eligible to recieve milestone payments under the agreement.
In addition, if approved, Pfizer intends to commercialize axitinib for this indication and SFJ will receive earn-out payments under the agreement.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!